Law firm Stephenson Harwood LLP has advised Stanley Capital Partners LLP (SCP) on its acquisition through its portfolio company, Drug Safety and Pharmacovigilance Services Solutions (DSS), of MyMeds&Me Limited (MMM).

DSS is a global provider of pharmacovigilance services, under the brand Bioclinica. Its acquisition of MMM, a UK headquartered digital pharmaceutical company, will allow it to continue building innovative pharmacovigilance technology, grow the company's technology-enabled platform and broaden the client-focused service offering. DSS is the fourth investment that SCP, a European and US-focused mid-market private equity firm, has led since its formation in 2019.

The Stephenson Harwood team was led by partner Malcolm MacDougall, who was supported by associates Rajiv Kakkad and Elliott Dagul.